Does Scales (NZSE:SCL) Have A Healthy Balance Sheet?




  • In Business
  • 2020-10-17 21:00:34Z
  • By Simply Wall St.
Does Scales (NZSE:SCL) Have A Healthy Balance Sheet?
Does Scales (NZSE:SCL) Have A Healthy Balance Sheet?  

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. Importantly, Scales Corporation Limited (NZSE:SCL) does carry debt. But should shareholders be worried about its use of debt?

When Is Debt Dangerous?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first step when considering a company's debt levels is to consider its cash and debt together.

View our latest analysis for Scales

What Is Scales's Debt?

You can click the graphic below for the historical numbers, but it shows that Scales had NZ$58.7m of debt in June 2020, down from NZ$66.4m, one year before. However, it does have NZ$112.0m in cash offsetting this, leading to net cash of NZ$53.2m.

A Look At Scales's Liabilities

We can see from the most recent balance sheet that Scales had liabilities of NZ$116.5m falling due within a year, and liabilities of NZ$145.5m due beyond that. On the other hand, it had cash of NZ$112.0m and NZ$86.6m worth of receivables due within a year. So its liabilities outweigh the sum of its cash and (near-term) receivables by NZ$63.4m.

Of course, Scales has a market capitalization of NZ$734.6m, so these liabilities are probably manageable. But there are sufficient liabilities that we would certainly recommend shareholders continue to monitor the balance sheet, going forward. Despite its noteworthy liabilities, Scales boasts net cash, so it's fair to say it does not have a heavy debt load!

On the other hand, Scales saw its EBIT drop by 7.1% in the last twelve months. That sort of decline, if sustained, will obviously make debt harder to handle. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if Scales can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. Scales may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Over the most recent three years, Scales recorded free cash flow worth 59% of its EBIT, which is around normal, given free cash flow excludes interest and tax. This free cash flow puts the company in a good position to pay down debt, when appropriate.

Summing up

While it is always sensible to look at a company's total liabilities, it is very reassuring that Scales has NZ$53.2m in net cash. So we are not troubled with Scales's debt use. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. Take risks, for example - Scales has 2 warning signs we think you should be aware of.

At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

COMMENTS

More Related News

Is Okta (NASDAQ:OKTA) Using Too Much Debt?
Is Okta (NASDAQ:OKTA) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Is There An Opportunity With Portmeirion Group PLC
Is There An Opportunity With Portmeirion Group PLC's (LON:PMP) 22% Undervaluation?

Does the October share price for Portmeirion Group PLC (LON:PMP) reflect what it's really worth? Today, we will...

Consti Plc Interim Report for January - September 2020
Consti Plc Interim Report for January - September 2020

CONSTI PLC INTERIM REPORT 28 OCTOBER 2020, at 8.30 a.m.Consti Plc Interim Report for January - September 2020                                       PROFITABILITY AND CASH FLOW IMPROVED7-9/2020 highlights (comparison figures in parenthesis 7-9/2019): ·Net sales EUR 68.2 (81.8) million; change -16.7% ·EBITDA EUR 3.2 (3.0) million and EBITDA margin 4.8% (3.6%) ·Operating profit (EBIT) EUR 2.5 (2.1) million and EBIT margin 3.6% (2.6%) ·Order backlog EUR 189.4 (206.4) million; change -8.2 % ·Free cash flow EUR 4.6 (-0.4) million ·Earnings per share EUR 0.21 (0.17)1-9/2020 highlights (comparison figures in parenthesis 1-9/2019): ·Net sales EUR 196.5 (236.5) million; change -16.9%...

Are Investors Undervaluing Tandem Diabetes Care, Inc. (NASDAQ:TNDM) By 27%?
Are Investors Undervaluing Tandem Diabetes Care, Inc. (NASDAQ:TNDM) By 27%?

Today we will run through one way of estimating the intrinsic value of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by...

Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited's (ASX:PAR) Intrinsic Value Is Potentially 45% Above Its Share Price

In this article we are going to estimate the intrinsic value of Paradigm Biopharmaceuticals Limited (ASX:PAR) by...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business